
Annexon, Inc (ANNX) Stock Forecast & Price Target
Annexon, Inc (ANNX) Analyst Ratings
Bulls say
Annexon is a biopharmaceutical company focused on developing C1q inhibitors for autoimmune and neurodegenerative diseases. Lead drug vonaprument has shown promising results in clinical trials for geographic atrophy and Guillain-Barré syndrome, but faces risks and potential competition. With FDA/EMA submissions accepted for another drug and a CFO with relevant experience, the company has potential for success in this market. Additionally, vonaprument has potential advantages over other treatments and a large market expected to generate significant revenue.
Bears say
Annexon is facing a number of challenges in its development and commercialization plans. The company's stock has a negative outlook, driven by concerns about the success of their lead drug vonaprument and potential competition from other approved drugs. While the company's Chief Innovation Officer, Dr. Ted Yednock, plays a key role in their complement platform, there are concerns about their ability to replicate success in larger trials and effectively market their products against larger competitors.
This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.
Annexon, Inc (ANNX) Analyst Forecast & Price Prediction
Start investing in Annexon, Inc (ANNX)
Order type
Buy in
Order amount
Est. shares
0 shares